Autonomix Medical's Nerve-Targeted Tech Selected for CRT 2026 Innovation Showcase
Event summary
- Autonomix Medical's presentation on transvascular precision-guided technology selected for oral presentation at CRT 2026's Best Innovation Competition.
- CEO Brad Hauser to present on March 9, 2026, in the International Ballroom – West.
- CRT's competition highlights transformative technologies with potential to impact patient care.
- Autonomix's technology focuses on catheter-based microchip sensing array for peripheral nerve signaling.
- Company initially developing technology for pancreatic cancer pain treatment, with broader applications in cardiology and chronic pain management.
The big picture
Autonomix Medical's selection for CRT 2026's Best Innovation Competition underscores the growing interest in precision nerve-targeted treatments. The company's technology aims to revolutionize the diagnosis and treatment of diseases involving the nervous system, addressing a significant unmet need in pain management and other conditions. The strategic focus on pancreatic cancer pain treatment highlights the potential for high-impact applications in a challenging clinical area.
What we're watching
- Clinical Validation
- How Autonomix's technology performs in initial trials for pancreatic cancer pain treatment.
- Market Expansion
- The pace at which Autonomix can expand its technology to other indications like cardiology and hypertension.
- Regulatory Approval
- Whether Autonomix can secure regulatory clearance for its investigational technology in the United States.
Related topics